Infantile fever-triggered acute liver failure caused by novel neuroblastoma amplified sequence mutations: a case report

Weiran Li 1,2, Yu Zhu 1,2, Qin Guo 1,2* and Chaomin Wan 1,2*

Abstract

Background: Infantile liver failure syndrome-2 (ILFS2) is caused by neuroblastoma amplified sequence (NBAS) mutation. The disease is characterized by recurrent episodes of acute liver failure (ALF) or by liver crisis triggered by recurrent episodes of fever and complete recovery.

Case presentation: Here, we describe the case of a Chinese girl with typical clinical manifestation of ILFS2 without exhibition of extrahepatic involvement. The patient harbored novel compound heterozygous mutations in the NBAS region (c.3386C > T (p.Ser1129Phe), c.1A > C (p.Met1Leu) and c.875G > A (p.Gly292Glu)), mutations which have not been previously reported. After administration of antipyretics and intravenous glucose and electrolyte administration, the patient recovered fully.

Conclusion: Through the present study, we recommend that ILFS2 should be taken into consideration during the differential diagnosis of children with recurrent, fever-triggered ALF. While the definitive diagnosis of ILFS2 remains dependent on genetic sequencing and discovery of NBAS, early antipyretic treatment is recommended to prevent liver crisis.

Keywords: NBAS, Acute liver failure, Infantile liver failure syndrome type 2, Whole exome sequencing

Background

Acute liver failure (ALF) is a rare condition in children, however, it is associated with a higher risk of mortality. Although the etiology of ALF in about 50% of cases remains unexplained [1], hereditary metabolic disorders comprise of a large number of ALF in pediatric populations [2, 3]. Recently, biallelic mutations in the neuroblastoma amplified sequence (NBAS) were reported as a novel cause of infantile liver failure syndrome-2 (ILFS2). ILFS2 is an autosomal recessive genetic disease characterized by recurrent episodes of ALF or liver crisis triggered by fever. Previously, the mutations within the NBAS were reported to be the cause of short stature, optic atrophy and Pelger-Huët anomaly of granulocytes (SOPH) syndrome in an isolated Russian yakut population [4]. Increasing research has reported that the phenotype spectrum of NBAS mutations ranges from isolated ILFS2 to a multi-systemic disease including short stature, skeletal dysplasia and optic atrophy [5–8]. Early administration of antipyretic and support therapy can effectively ameliorate the course of ILFS2 due to NBAS mutations, improving the prognosis [8, 9]. Thus, it is important to confirm the diagnosis of ILFS2 at the earliest stage possible. Here, we report a case of isolated ILFS2 caused by novel NBAS mutation in a Chinese girl aged 3 years and 8 months. This report also reviews NBAS-related cases in the medical literature.
Case presentation
A 3 year and 8 month old Chinese girl born at term to healthy, non-consanguineous parents by normal vaginal delivery had no family history of liver disease. At the age of 2 years and 11 months, the patient presented recurrent fever with cough, vomiting, decreased activity, and lethargy agitated for 3 weeks upon admission to our hospital. She had severe jaundice without hepatomegaly, however the rest of the physical examinations (growth and development, skeletal system, nervous system and motor ability, integument and facial profile) were normal. Laboratory evaluations indicated extreme damage to liver functions and severe coagulopathy (Table 1). Serum creatinine (Cre) and blood urea nitrogen (BUN) were normal. Creatine kinase (CK) and cardiac troponin I (cTnI) were mildly elevated at 149 U/L (normal range: 30–135) and 0.055μg/L (normal range: 0–0.034) respectively, suggesting myocardial injury. The white blood cell (WBC) count was significantly increased (15.8*10⁹/L, normal range:3.6–13) and neutrophils accounted for 81% (12.77*10⁹/L, normal range:0.72–4.80).

C-reactive protein (CRP) was also elevated (39 mg/L, normal range:0–8). The patient was diagnosed with ALF and managed with antipyretics, plasmapheresis, hepatoprotectives (e.g., Polyene Phosphatidyl Choline and Ademetionine Butanedisulfonate) and intravenous infusion of glucose and potassium chloride. Following treatment, the liver function of the patient was restored completely.

Eight months later, at the age of 3 years and 7 months, the patient was readmitted during a second episode of liver crisis following an upper respiratory tract infection with fever (up to 39 °C) and cough. Physical examinations revealed mild jaundice with an enlarged liver (palpable 2.5 cm below the costal margin). Laboratory data indicated a recurrence of significant damage of liver function and severe coagulopathy (Table 1). The value of CK, cTnI, Cre and BUN were normal during this episode and the trends of WBC and CRP were similar to those of the first episode. Again, after treatment including antipyretics, antibiotics, hepatoprotectives and intravenous glucose and potassium chloride, the patient fully recovered.

At the age of 3 years and 8 months, the patient was once again re-admitted with ALF after a 12 h persistence of fever (maximum temperature: 39.3 °C) and vomiting. Physical examination revealed hepatomegaly (palpable 1.5 cm below the costal margin), a few bleeding spots in her chest, and herpes in her right soft palate along with an ulcer (3*3 mm) in the right isthmus of fauces. No jaundice was observed. The clinical features and elevation of liver enzymes with coagulopathy were similar to previous episodes (Table 1). Coxsackievirus A16 nucleic acid detection was positive. Other laboratory results presented similar changes to those observed during the second episode. Complete recovery of the patient was

| Table 1 Clinical features and laboratory results of the presented patient |
| --- |
| Clinic features & laboratory results | Result |
| Symptom | Age of 2 year and 11 months | Age of 3 year and 7 months | Age of 3 years and 8 months |
| Body sign | Recurrent fever | Mild Jaundice, Hepatomegaly | Fever with vomit |
| Severe Jaundice | | | Hepatomegaly, A few bleeding spots in her chest, Herpes in right soft palate, An ulcer (3*3 mm) in right isthmus of fauces |
| Max temperature (°C) | >38.5 | 39.0 | 39.3 |
| ALT(U/L) (Normal range:9–52) | 9787 | 6378 | 4096 |
| AST (U/L) (Normal range:14–36) | 12,489 | 9924 | 4857 |
| TBL (umol/L) (Normal range:3–22) | 44.3 | 22.4 | 28.4 |
| DBIL (umol/L) (Normal range:0–5) | 7.30 | 16.9 |
| IBIL (umol/L) (Normal range:0–19) | 20.20 | 15.10 | 11.50 |
| Albumin (g/L) (Normal range:35–50) | 41.9 | 44.1 | 36.8 |
| γ-GT (U/L) (Normal range:12–43) | 26 | 48 | 42 |
| LDH (U/L) (Normal range:313–618) | 21,786 | 22,854 | 6492 |
| PT (s) (Normal range:8.7–14.7) | 63.9 | 15.6 | 25.9 |
| INR (Normal range:0.8–1.5) | 5.50 | 1.48 | 2.47 |
| APTT (s) (Normal range:17.5–37.5) | 45.0 | 25.1 | 25.5 |
| FIB (mg/dL) (Normal range:200–400) | 221 | 327 | 310 |
| TT (s) (Normal range:14–21) | 24.1 | 20.2 | 19.1 |

NA Not available, ALT Alanine transaminase, AST Aspartate aminotransferase, TBL Total bilirubin, DBIL Direct Bilirubin, IBIL Indirect Bilirubin, γ-GT γ-glutamyl transpeptidase, LDH Lactate dehydrogenase, PT Prothrombin time, INR International normalized ratio, APTT Activated partial thromboplastin time, FIB Fibrinogen, TT Thrombin time
achieved with a similar treatment plan to the previous admission.

During the three admissions, metabolic evaluations indicated hyperammonemia (40.0 umol/L; Normal range: 9–30) and hypoglycemia (3.77 mmol/L; Normal range: 4.1–5.9). Lactate, ceruloplasmin, alpha-fetoprotein and pyruvate values were all normal. However, there was a remarkable elevation of β-hydroxybutyrate (1.81 mmol/L; Normal range:0–0.27). Serum amino acid test presented elevations of piperolic acid (551.318 μM; normal range: 100–438) and the ratio of leucine to alanine (1.359; normal range:0.06–1.00). The values of acyl carnitines were normal in the plasma. Metabolic biomarkers in the urine showed that the value of ketone bodies, methione, adenine and adenosine were all increased. The immunological indicators including complement C3 and C4 levels, serum immunoglobulin levels and the count of T lymphocyte, B lymphocyte, natural killer cells, and helper T cells were all unremarkable. Further, a panel of serology tests for infectious agents including HIV virus, treponema pallidum, hepatitis B virus, hepatitis C virus, Epstein-Barr virus, toxoplasma, rubella virus and herpes simplex virus were all negative. No Pelger–Huët anomaly of granulocytes was found in either of multiple blood smears. A percutaneous liver biopsy was undertaken at the third admission. This showed nonspecific, mild acute hepatitis with hydropic degeneration of hepatic cells and small foci of lobular necrosis. There were a small number of lymphocytes, monocytes and plasma cells infiltrating in the portal area. Foot and Masson stain showed fibroplasia and the enlargement of some portal areas. Berlin blue, rhodamine, rubeanic acid, Periodic Acid-Schiff and diastase periodic acid-Seiff stain were normal. In order to identify the cause for recurrent ALF, whole exome sequencing was performed in the patient and her parents. Three rare heterozygous mutations in the NBAS gene were detected: c.3386C > T (p.Ser1129Phe), c.1A > C (p.Met1Leu) and c.875G > A (p.Gly292Glu), the latter of which have not been previously reported. Parental genotyping showed that the c.3386C > T (p.Ser1129Phe) and c.875G > A (p.Gly292Glu) mutation occurred in a heterozygous state in the mother and the c.1A > C (p.Met1Leu) mutation in a heterozygous state in the father, presenting compound heterozygosity of the NBAS variants in the girl. According to the guidelines of The American College of Medical Genetics Genomics and the Association for Molecular Pathology (ACMG), the pathogenicity of the c.1A > C (p.Met1Leu) mutation was greater than 90%. The pathogenicity of the other two mutations, however, was uncertain. Prediction of protein biological function was carried out with software including SIFT, MutationTaster and GERP++, which indicated that two of the mutations (c.3386C > T (p.Ser1129Phe) and c.1A > C (p.Met1Leu)) were pathogenic while the c.875G > A (p.Gly292Glu) mutation was nonpathogenic. Specifically, for the mutation of c.3386C > T (p.Ser1129Phe), the score and prediction of SIFT, MutationTaster and GERP++ were (0.001, damaging), (1, disease causing) and (5.74, conserved) respectively. Regarding the mutation of c.1A > C (p.Met1Leu), the score and prediction of SIFT, MutationTaster and GERP++ were (0, damaging), (1, disease causing) and (5.2, conserved) respectively. For the mutation of c.875G > A (p.Gly292Glu), these values were (1, tolerated), (1, polymorphism) and (–3.5, nonconserved) respectively.

Discussion and conclusions

ILFS2 is a rare condition characterized by episodic liver failure or crisis triggered by recurrent fever. Liver function can be fully recovered after conservative treatment. It was first reported by Haack et al. that ILFS2 is caused by biallelic mutations in the NBAS gene [10]. NBAS mutations have also been identified in SOPH syndrome patients without liver failure [4]. An increasing number of studies have indicated that diseases based on NBAS mutations have a broad phenotypic spectrum, ranging from isolated recurrent ILFS2 to a multi-systemic disease manifesting as short stature, skeletal dysplasia, dysmorphism and optic atrophy with or without liver failure [4–9, 11–18].

A literature search found 56 reported cases of NBAS-associated disease (Table 2). The median onset age of these patients was 0.8 years (interquartile range:0.1–6.7 years) however only 47 patients were considered due to missing data of onset age. The ratio of female to male patients was 17 to 13, however, only 30 patients were analyzed due to incomplete data of sex. The clinical manifestations of the hereditary disease were characterized by two aspects including intrahepatic and extrahepatic symptoms. On the one hand, the phenotype of liver illness is usually triggered by febrile illness and manifested as recurrent ALF or liver crisis, where complete recovery is typical during the interval of episodes. It usually begins with rapid increased value of alanine transaminase and aspartate transaminase, indicating functional liver damage. Mild to severe coagulopathy, jaundice and hepatomegaly are manifested in most cases. Secondary metabolism disorders, such as elevation of lactate and serum ketone bodies, hypoglycemia, and hyperammonemia are sometimes observed in these patients [7, 9]. Moreover, some patients present hepatic encephalopathy or death due to untimely treatment. On the other hand, the main extrahepatic manifestation of NBAS mutations are short stature, skeletal dysplasia, optic atrophy, Pelger-Huët anomaly of granulocytes or immunological abnormalities [7, 13, 17]. Previous researchers have reported that among the 56 reported patients with NBAS-associated disease, 43 patients (76.8%)
| Patient ID | Sex | Nationality | Genotype | Onset of ALF or LC (Year) | Age at last visit (Year) | Number of ALF | Number of LC | ALF or LC Fever depended | Skeletal system and musculature | Typical morphological characteristics | Integument (Cutis laxa) | Nervous system | Immune system | Pelger Huët anomaly | Other clinical manifestations |
|------------|-----|-------------|----------|--------------------------|--------------------------|----------------|----------------|----------------------------|---------------------------------|---------------------------------|--------------------------|---------------|---------------|-----------------|-------------------|-------------------------------------|
| 1          | F   | Germany     | c.[558_560del]; [680dup]; p.[Ile187del]; Ser230Ile | 1.8                      | 18                       | 2              | 12             | YES                        | Short stature (~2.67SD)         | NA                               | NA                       | Optic atrophy | NO             | NO              | Hypotelorism       |                                     |
| 2          | F   | Germany     | c.[2708 T > G]; [680dup]; p.[Arg1004*]; Ser230Arg | 0.6                      | 22                       | 7              | 6              | YES                        | Short stature (~2083SD)         | NA                               | NA                       | Epilepsy; Learning disability (IQ 77) | NO             | NO             | No              | Acute renal failure; Hypotelorism  |                                     |
| 3          | F   | Germany     | c.[603_605del]; [3164 T > C]; p.[Arg1004*]; Leu1055Pro | 0.8                      | 18                       | 5              | 8              | YES                        | Short stature (~4.24SD)         | NA                               | NA                       | NO             | NO             | No              | Hypotelorism; disease             |                                     |
| 4          | F   | Germany     | c.[2708 T > G]; [2827G > T]; p.[Arg1004*]; Leu1055Pro | 0.7                      | 37                       | NA             | NA             | YES                        | Short stature (~2.25SD)         | NA                               | NA                       | Coordination deficit; Intellectual disability (IQ 50) | NO             | NO             | No              | Hypotelorism       |                                     |
| 5          | M   | Germany/    | c.[3010C > T]; [3164 T > C]; p.[Arg1004*]; Leu1055Pro | 0.6                      | 14                       | 10             | 4              | YES                        | NO                               | NA                               | NA                       | NO             | NO             | No              | Hypotelorism; Cardiomyopathy       |                                     |
| 6          | M   | Great Britain | c.[1533_1545del]; [2951 T > G]; p.[Ser179Thr]; Leu1055Pro | 1.5                      | 3                        | 5              | 2              | YES                        | Short stature (~2.91SD)         | NA                               | NA                       | Motor delay | NO             | NA              |                                  |                                     |
| 7          | F   | Croatia     | c.[1040C > T]; [2203_3C > G]; p.[Pro348Ser]; [1040C > T] | 0.9                      | 9                        | 4              | 5              | YES                        | NO                               | NA                               | NA                       | NO             | NO             | No              | Hypotelorism       |                                     |
| 8          | F   | Croatia     | c.[1040C > T]; [2203_3C > G]; p.[Pro348Ser]; [1040C > T] | 6.7                      | 11                       | 1              | 2              | YES                        | Short stature (~2.71SD)         | NA                               | NA                       | NO             | YIS             | NO              | Erythema nodosum; Crohn's disease  |                                     |
| 9          | M   | Germany/Turkey | c.[1187G > A]; [2330C > A]; p.[Thr396*]; [Pro774His] | 1.8                      | 8                        | 1              | 3              | YES                        | NO                               | NA                               | NA                       | NO             | NO             | NO              |                                  |                                     |
| 10         | F   | United States | c.[118-2A > G]; [2324G > T]; p.[Thr396*]; [Val642Phe] | 1.5                      | 4                        | 3              | NA             | YES                        | Short stature (~2.62SD)         | NA                               | NA                       | NO             | NO             | NA              | Episodes of mild hypoglycemia during acute illness |                                     |
| 11         | F   | United States | c.[603_605del]; [3164 T > C]; p.[Ser230Ile]; Leu1055Pro | 0.3                      | 18                       | 5              | 2              | YES                        | Short stature (~2.35SD)         | NA                               | NA                       | NO             | NO             | NO              |                                  |                                     |
| 12         | M   | France       | c.[2827G > T]; [3164 T > C]; p.[Pro348Ser]; [1040C > T] | 0.6                      | 18                       | 8              | 0              | YES                        | Short stature (~2.48SD)         | NA                               | NA                       | Optic atrophy; Left hemiparesis; Motor delay; Epilepsy; Hypotelorism | No             | NO             | Hypogammaglobulinemia | Yes | Lymphopenia during crisis; Neuroblastoma |                                     |
| 13         | M   | Germany      | c.[1278A > G]; [3164 T > C]; p.[Pro348Ser]; [1040C > T] | 0.8                      | 8                        | 1              | 3              | YES                        | Short stature (~2.07SD)         | NA                               | NA                       | NO             | NO             | Yes             | Hypogammaglobulinemia | NO |
Table 2 Clinical features of patients with NBAS deficiency reported in previous studies (Continued)

| Patient ID | Sex | Nationality | Genotype | Onset age of ALF or LC (Year) | Age at last visit (Year) | Number of ALF | Number of LC | ALF or LC Fever depended | Skeletal system and musculature | Typical morphological characteristics | Integument (Cutis laxa) | Nervous system | Immune system | Pelger-Huët anomaly | Other clinical manifestations |
|------------|-----|-------------|----------|-------------------------------|--------------------------|-----------------|--------------|--------------------------|-------------------------------|--------------------------------|------------------------|--------------|-------------|------------------|-----------------------------|-----------------------------|
| 14         | F   | Germany     | c.[173-2A > G]; [3363A > G]; [I1121Met] | 2                             | 16                        | 12              | 1            | YES                      | NO                           | NA                         | NA                     | NA           | NA           | NA               | NO                          |
| 15         | F   | American    | c.[409C > T];[1186T > A] p.[Arg1377Trp]; [Trp396Arg] | 1.9                           | 5                          | 3              | NA           | YES                      | Short stature (<−3SD); Skeletal dysplasia; Cervical instability; Fractures (1 skull and 1 left femur fracture); | YES                         | YES                     | Motor delay | Reduced natural killer cells | YES                          | NO                          |
| 16         | M   | Switzerland | c.[284C > T];[850A > T] p.[Arg59Val]; [Ile284Thr] | 0.4                           | 12                        | 0              | >1           | YES                      | Short stature (<−3SD); Skeletal dysplasia; Cervical instability; | YES                         | YES                     | Optic atrophy | Hypogammaglobulinemia; Reduced natural killer cells | YES                          | NO                          |
| 17         | F   | NA          | c.[2819A > C] p.[Val940Pro] | 0.3                           | 4                          | ≥1            | ≥1           | YES                      | Short stature NO NO NO NO NO NO NA NA |                          |                          |                          |                             |
| 18         | M   | Japanese    | c.[1018G > C];[2674G > T] p.[Gly340Arg]; [Val892Pro] | 3.3                           | 3.5                        | 2              | 0            | YES                      | Short stature NO NA NO NO NO NO NO |                          |                          |                          |                             |
| 19         | F   | China       | c.[1840delG] p.[Ala614Leufs*3]; [Cys1199Tyr] | 0.5                           | 0.58                       | 1              | 2            | YES                      | NO                           | NO                         | NO                     | NA           | NO           | NA               | NO                          |
| 20         | M   | China       | c.[6751_6754delCTCC]; [3596-G > A] p.[Ile2252Cysfs*5]; [Cys1199Tyr] | 1.2                           | 5.4                        | ≥2            | ≥3           | YES                      | NA                           | NA                         | NA                     | NA           | NA           | Reduced natural killer cells | YES                          | NO                          |
| 21         | M   | China       | c.[7041_7043delCCT]; [3759delC] p.[2347_2348delLMil]; [Thr1256Valfs*16] | NA                            | 0.75                       | NA            | ≥2           | YES                      | NO                           | NO                         | NO                     | NO           | NO           | YES               | NO                          |
| 22         | F   | China       | c.[3596G > A];[209 + 1G > A] p.[Cys1199Tyr] | NA                            | 4                          | NA            | ≥1           | YES                      | NO                           | NO                         | NO                     | NA           | NA           | NO               | NO                          |
| 23         | M   | China       | c.[6611_6612insCA]; [3596G > A] p.[Met2204Ifs*3]; [Cys1199Tyr] | 0.5                           | 6.9                        | 5             | 3            | YES                      | Short stature (<−1.4SD) NO NO NO NO NO NO |                          |                          |                          |                             |
| 24         | M   | China       | c.[3596G > A]; [586C > T] p.[Ile1999Val] | 0.6                           | 4.7                        | 1             | 2            | YES                      | Short stature (<−1.4SD) NO NO NO NO NO NO |                          |                          |                          |                             |
| 25         | M   | China       | c.[3596 + 1G > T]; [2407G > A] p.[?]; | 0.5                           | 2.3                        | 10            | 1            | YES                      | NO                           | NO                         | NO                     | NO           | NO           | NA               | NO                          |
| Patient ID | Sex | Nationality | Genotype | Onset age of ALF or LC (Year) | Age at last visit (Year) | Number of ALF of LC | ALF or LC Fever depended | Skeletal system and musculature | Typical morphological characteristics | Integument (Cutis laxa) | Nervous system | Immune system | Pelger Huët anomaly | Other clinical manifestations |
|------------|-----|-------------|----------|-------------------------------|--------------------------|---------------------|------------------------|-----------------------------|-------------------------------------|-----------------|----------------|----------------|--------------------------|-----------------------------|
| 26         | F   | NA          | c.[2827G > T]; c.[5741G > A]; [Glu803lys]; [Arg1914His] | 0.7                         | 4.9                       | NA                  | ≥2                    | YES                         | Short stature; Low bone mineral density; Skeletal dysplasia; Delayed bone maturation; Hypotonia | YES             | NA             | Optic atrophy; Motor delay; Speech delay | Reduced B cells; Initially neutropenia; Hypogammaglobulinemia | YES NO |
| 27         | F   | Portuguese  | c.[580A > C]; [1749G > A]; p.[His627Phe]; [Trp934*] | 2.8                         | 3.9                       | 0 2                 | YES                   | YES                         | Short stature; Poor muscular development; Slightly delayed bone age (18 months at 23 months of age); | YES             | NO             | NO             | NO                       | NA NO |
| 28         | F   | Portuguese  | c.[680A > C]; [1749G > A]; p.[His627Phe]; [Trp934*] | 1.5                         | 9                         | 2 >30                | YES                   | NO                         | Short stature; Low bone mineral density | NO             | NO             | NO             | NO                       | NA NO |
| 29         | NA  | NA          | c.[284C > T]; c.[680A > C]; [5741G > A]; p.[Ala95Val]; [Trp934*] | NA                          | NA                        | ≥1                   | NA                    | NA                         | Short stature; Cervical instability; Reduced bone mineral density; Muscular hypotrophy | NA             | YES            | Motor delay         | Hypogammaglobulinemia | NO High pitched voice |
| 30         | NA  | NA          | c.[812 T > C]; [812 T > C]; p.[Leu271Pro]; [Leu271Pro] | NA                          | NA                        | ≥1                   | NA                    | NA                         | Short stature; Muscular hypotonia and hypotrophy | NA             | NO             | Motor delay         | Hypogammaglobulinemia | NO Protuberant abdomen; High pitched voice |
| 31         | NA  | NA          | c.[1241C > T]; c.[1241C > T]; p.[Ser414Phe]; [Ile984Leufs*8] | 0.2                         | NA                        | ≥1                   | NA                    | NA                         | Short stature; Skeletal dysplasia; Reduced bone mineral density; Pathologic fracture; Muscular hypotonia and hypotrophy | NA             | YES            | Optic atrophy        | Hypogammaglobulinemia | YES Insulin dependent diabetes mellitus; Chronic lung disease; High pitched voice |
| 32         | NA  | NA          | c.[1241C > T]; c.[6236 + 1_6237]; c.[6432 + 1_6433]; [Glu2080*] | 0.7                         | NA                        | 0 ≥1                 | NA                    | NA                         | Short stature; Skeletal dysplasia; Reduced bone mineral density; Muscular hypotonia and hypotrophy | NA             | YES            | Optic atrophy        | Motor delay             | NO YES Relative macrocephaly; Decreased serum IGF1 and IGFBP3; High pitched voice |
| 33         | NA  | NA          | c.[3041_5048del]; [5049_5050ins]; p.[Arg517Cys]; [Ser661Gln*17] | 0.7                         | NA                        | ≥1                   | NA                    | NA                         | Reduced bone mineral density; Skeletal dysplasia; | NA             | NO             | NO             | Hypogammaglobulinemia | NO Cataract and dislocation of the lens; Nephrolithiasis; High pitched voice |
| Patient ID | Sex | Nationality | Genotype                                                                 | Onset age of ALF or LC (Year) | Age at last visit (Year) | Number of ALF | Number of LC | ALF or LC Fever depended | Skeletal system and musculature                                                   | Typical morphological characteristics | Integument (Cutis laxa) | Nervous system | Immune system | Pelger-Huët anomaly | Other clinical manifestations |
|-----------|-----|-------------|---------------------------------------------------------------------------|-----------------------------|--------------------------|-------------------|---------------|-------------------------|---------------------------------------------------------------------------------|-------------------------------------|--------------------------|----------------|----------------|------------------------|-----------------------------|
| 34        | NA  | NA          | c.[1550G > A]; [6805G > T]; p.[Arg517His]; [Glu2269*]                  | 3.0                         | NA                       | NA                | NA            | NA                      | Fever depended; Pathologic fracture; Muscular hypotonia and hypotrophy           |                                     |                          |               |              |                       |                              |
| 35        | NA  | NA          | c.[1550G > A]; [6805G > T]; p.[Arg517His]; [Glu2269*]                  | NA                          | NA                       | NA                | NA            | NO                      | NO                                                                              |                                     |                          |               |              |                       |                              |
| 36        | NA  | NA          | c.[2191A > G]; p.[Thr731Pro]; [Thr731Pro]                              | 1                            | NA                       | 1                 | NA            | NO                      | NO                                                                              |                                     |                          |               |              |                       |                              |
| 37        | NA  | NA          | c.[2330C > A]; [2330C > A]; p.[Pro777His]; [Pro777His]                | 2.7                         | NA                       | 1                 | NA            | NO                      | NO                                                                              |                                     |                          |               |              |                       |                              |
| 38        | NA  | NA          | c.[2330C > A]; [2330C > A]; p.[Pro777His]; [Pro777His]                | 3.2                         | NA                       | 1                 | NA            | NO                      | NO                                                                              |                                     |                          |               |              |                       |                              |
| 39        | NA  | NA          | c.[2809C > G]; [5138 + 1_5139–1]; p.[Pro937Ala]; [Ile1121Met]         | 0.7                         | NA                       | 1                 | NA            | NO                      | NO                                                                              |                                     |                          |               |              |                       |                              |
| 40        | NA  | NA          | c.[2819A > G]; [984G > T]; p.[Thr940Pro]; [Thr940Pro]                | 0.2                         | NA                       | 1                 | NA            | NO                      | NO                                                                              |                                     |                          |               |              |                       |                              |
| 41        | NA  | NA          | c.[2951T > G]; [5827G > T]; p.[Thr940Pro]; [Glu934*]                 | 2.6                         | NA                       | 1                 | NA            | NO                      | NO                                                                              |                                     |                          |               |              |                       |                              |
| 42        | NA  | NA          | c.[3164T > C]; [5027 + 1_5028–1]; [5724 + 1_5725–1]; p.[Leu1055Pro]; [Glu1676Aspfs*10] | 1.3                         | NA                       | 1                 | NA            | NO                      | NO                                                                              |                                     |                          |               |              |                       | Hypogammaglobulinemia        |
| 43        | NA  | NA          | c.[3363A > G]; [3363A > G]; p.[Leu1121Met]                           | 1.0                         | NA                       | 0                 | 21            | NA                      | NO                                                                              |                                     |                          |               |              | Hypogammaglobulinemia    |                              |
| 44        | NA  | NA          | c.[3388C > T]; [3388C > T]                                            | 2.3                         | NA                       | 1                 | NA            | NO                      | NO                                                                              |                                     |                          |               |              |                       | Elevated 3-    |
|           |     |             |                                                                          |                              |                                |                        |                        |                                |                        |

Li et al. BMC Gastroenterology (2020) 20:308
| Patient ID | Sex  | Nationality | Genotype | Onset age of ALF or LC (Year) | Age at last visit (Year) | Number of ALF | Number of LC | ALF or LC Fever depended | Skeletal system and musculature | Typical morphological characteristics | Integument (Cutis laxa) | Nervous system | Immune system | Pelger Huët anomaly | Other clinical manifestations |
|------------|------|-------------|----------|-------------------------------|-------------------------|----------------|-------------|--------------------------|---------------------------------|----------------------------------|-------------------------|----------------|----------------|----------------|-----------------------------|
| 45         | NA   | NA          | p.(Ser1129Phe); p.(Ser1129Phe); [Ser1129Phe]; [Ser1129Phe] | 1.8                       | ≥1                       | NA           | NA          | NO                       | NO                             | NO                              | NO                      | NO            | NO             | NO             | Elevated 3-methylglutaryl-CoA and 3-methylglutaryl-CoA in urine |
| 46         | NA   | NA          | c.(3386C > T); p.(Ser1129Phe); [Ser1129Phe]; [Ser1129Phe] | 0.8                       | ≥1                       | NA           | NA          | NO                       | NO                             | NO                              | NO                      | NO            | NO             | NO             | Hypogammaglobulinemia and 3-methylglutaryl-CoA and 3-methylglutaryl-CoA in urine |
| 47         | NA   | NA          | c.(3602A > C); [3602A > C]; p.(Gln1201Pro); [Gln1201Pro] | 0.8                       | ≥1                       | NA           | NA          | NO                       | NO                             | NO                              | NO                      | NO            | NO             | NO             | During crisis: seizures, cholecystitis, truncal edema, hypophosphatemia, anemia, lymphopenia, decrease of neutrophils |
| 48         | NA   | NA          | c.(5741G > A); [1528C > T]; p.(Arg1914His); [Arg510*] | NA                         | 0                       | ≥1           | NA          | NO                       | NO                             | NO                              | NO                      | NO            | NO             | NO             | Liver transplantation |
| 49         | NA   | NA          | c.(5740C > G); [6877delC]; p.(Arg1914Gly); [Leu293GluGlu*9] | 0.5                       | ≥1                       | NA           | NA          | NO                       | NO                             | YES                             | NO                      | NO            | NO             | NO             | Hypogammaglobulinemia and 3-methylglutaryl-CoA and 3-methylglutaryl-CoA in urine |
| 50         | NA   | NA          | c.(5761G > C); [688dup]; p.(Ala1921Pro); [Ser2030His*4] | 0.4                       | 0                       | ≥1           | NA          | NO                       | NO                             | NO                              | NO                      | NO            | NO             | NO             | Optic atrophy; Motor delay |
| 51         | NA   | NA          | c.(6840G > T); [6840G > T]; p.(T171) | 0.3                       | 0                       | ≥1           | NA          | NO                       | NO                             | NO                              | NO                      | NO            | NO             | NO             | Optic atrophy; Motor delay |
| 52         | NA   | NA          | c.(6966_6999delinsTC); [5547delC]; p.(Gln2302His*18) | 4.5                       | 0                       | ≥1           | NA          | NO                       | NO                             | NO                              | NO                      | NO            | NO             | NO             | Optic atrophy; Motor delay |

Table 2: Clinical features of patients with NBAS deficiency reported in previous studies (Continued)

Li et al. BMC Gastroenterology (2020) 20:308
Table 2: Clinical features of patients with NBAS deficiency reported in previous studies (Continued)

| Patient ID | Sex  | Nationality | Genotype                                                                                                                                                                                                 | Onset age of ALF or LC (Year) | Age at last visit (Year) | Number of ALF | Number of LC | ALF or LC Fever depended | Skeletal system and musculature                                                                 | Typical morphological characteristics | Integument (Cutis laxa) | Nervous system | Immune system | Pelger-Huët anomaly | Other clinical manifestations |
|------------|------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------|--------------------------|----------------|-------------|--------------------------|---------------------------------------------------------------------------------------------|---------------------------------|---------------------|---------------|---------------|-------------------|------------------------------------------------|
| 53         | NA   | NA          | c.[767G > A]; p.[Cys256Tyr]; [Pre671Cys]                                                                                                                                                                   | 0.1                          | NA                       | 0              | ≥1          | NA                       | Short stature                                                                                   | NA                               | NA                  | Motor delay     | NO            | NO                | NO                                                          |
| 54         | NA   | NA          | c.[2535G > T]; p.[Val845Ile]; [Ala192Pro]                                                                                                                                                                | NA                           | NA                       | 0              | ≥1          | NA                       | Short stature                                                                                   | NA                               | NA                  | NO            | NO            | NO                | NO                                                          |
| 55         | M    | Italy       | c.[6840G > A]; [698dupT]; p.[Gly2238_Thr2280del]; [Ser2306Glu*4]                                                                                                                                         | NA                           | 7                        | 0              | ≥1          | NA                       | Short stature; Skeletal dysplasia; Reduced bone mineral density; Neurodevelopmental delay with normal intelligence | YES                             | NA                  | Hypogammaglobulinemia | YES | Congenital bilateral glaucoma; Primary hypothyroidism |                                               |
| 56         | F    | Italy       | c.[6840G > A]; [1501C > T]; p.[Gly2238_Thr2280del]; [Arg501*]                                                                                                                                       | NA                           | 4                        | 0              | ≥1          | NA                       | Short stature; Skeletal dysplasia                                                                 | YES                             | NA                  | Hypogammaglobulinemia | YES | Premature birth; Retinopathy of prematurity |                                               |

NA: Not available, ALF: Acute liver failure, LC: Liver crisis; Patients 1 to 14 were published by Staufner C et al. [8]; Patients 15 to 16 were published by Segarra NG et al. [5]; Patient 17 was published by Hasosah MY et al. [11]; Patient 18 was published by Ono S et al. [7]; Patient 19 was published by Yucan Zheng [14]; Patient 20 was published by Xuerui Song [12]; Patient 21 was published by Jiali Gu [13]; Patient 22 was published by Wang J [15]; Patient 23 to 25 were published by Li JQ [9]; Patient 26 was published by Cortum [6]; Patient 27 to 28 were published by Regateiro FS [16]; Patient 29-54 was published by Staufner [17]; Patient 55 to 56 were published by Carli [18].
presented ILFS2 with multi-systemic manifestations, where short stature was the most common extrahepatic manifestations (34/43, 79.1%). Only 13 cases (23.2%) presented isolated ILFS2 (Table 2). The present case reported a 3 years and 8 months old girl with ILFS2 who experienced the first episode at 2 years and 11 months of age and it presented herein details isolated ILFS2 with coagulopathy, jaundice and hepatomegaly, where no extrahepatic abnormalities were observed. We speculated that the clinical manifestations may be associated with the different gene mutation profile of this patient.

Although the clinical manifestation of ILFS2 in this case report was typical, the definitive diagnosis of this disease depended on whole exome sequencing as it was important to rule out ALF caused by drugs, infection or simultaneous autoimmune abnormality. Many mutation sites in the NBAS gene have been reported [5, 7, 8]. Through NBAS sequencing, it was determined that three heterozygous mutations occurred in the patient under discussion. Specifically, \( c.3386C>T \) (p.Ser1129Phe), \( c.1A>C \) (p.Met1Leu) and \( c.875G>A \) (p.Gly292Glu). Regarding the \( c.3386C>T \) (p.Ser1129Phe) mutation, Stauffer et al. have reported that two patients who harbored this mutation similarly presented ALF without other extrahepatic manifestations [17]. The onset age of those two patients were 2.3 and 1.8 years respectively, close to the age of onset for our patient (2.9 years). Stauffer et al. indicated that the \( c.3386C>T \) (p.Ser1129Phe) mutation affected the region coding for the Sec39 domain of the NBAS gene, which is necessary for tethering at the endoplasmic reticulum (ER) in the syntaxin18 [17]. The \( c.1A>C \) (p.Met1Leu) mutation is a likely pathogenic mutation (90% pathogenicity) according to the guidelines of the ACMG. Further, the software for the prediction of protein biological function have also indicated that this mutation is likely pathogenic. Thus, we speculated that the mutations including \( c.3386C>T \) (p.Ser1129Phe) and \( c.1A>C \) (p.Met1Leu) are associated with the IFS2 while the \( c.875G>A \) (p.Gly292Glu) mutation was likely nonpathogenic.

To date, the molecular pathogenesis of ALF in NBAS deficiency has remained unclear. The biological role of NBAS is two-fold. As a subunit of the syntaxin18 complex which is thermally susceptible, it is associated with Golgi-to-ER retrograde transport [19]. On the other hand, NBAS plays an important role in nonsense-mediated mRNA decay control [20]. The dysfunction of the syntaxin 18 complex caused by NBAS deficiency may alter Golgi-to-ER retrograde vesicular trafficking, which in turn may lead to liver dysfunction and eventually, failure [8, 10].

Complete recovery of liver function in patients with IFLS2 can be achieved through comprehensive treatment. Therapeutic experience shows that early antipyretic therapy and treatment of the primary diseases that trigger fever is effective and able to prevent life-threatening ALF. Additionally, support treatments including intravenous infusion of lipid and glucose to maintain the internal environment stable and energy replete expedite recovery [8, 11]. Generally, liver transplantation is not considered unless intensive conservative treatment is ineffective. The patient in our study received antipyretics in addition to other conservative strategies including plasmapheresis (only in first episode), hepatoprotectives and intravenous glucose and electrolyte infusion. These treatments led to a remarkable recovery.

The present case detailed the course of a Chinese girl with ILFS2 presenting typical clinical characteristics of the disease-without the involvement of extrahepatic systems. The patient was found to harbor novel compound heterozygous mutations in the NBAS (\( c.3386C>T \) (p.Ser1129Phe), \( c.1A>C \) (p.Met1Leu) and \( c.875G>A \) (p.Gly292Glu)), two mutations of which have not been previously reported. Here we suggest that ILFS2 should be considered as a part of the differential diagnoses of children presenting with recurrent ALF triggered by fever. However, the definitive diagnoses of ILFS2 continues to depend on sequencing results of NBAS as well as the elimination of other potential causes of ALF including drug reactions, infections and autoimmune hepatitis. Early and effective antipyretic and support treatments such as intravenous lipid and glucose infusion are also recommended as these can prevent further liver crisis and lead to faster recovery.

**Abbreviations**

ALF: Acute liver failure; NBAS: Neuroblastoma amplified sequence; ILFS2: Infantile liver failure syndrome-2; SOPH: Optic never atrophy and mental retardation; GDHB: Glutathione disulfide reductase; HPA: Hypoparathyroidism; AGD: Adrenal gland dysplasia; CrLC: Creatine kinase; cTnI: Cardiac troponin I; WBC: White blood cell; CRP: C-reactive protein; ACMG: The American College of Medical Genetics Genomics and the Association for Molecular Pathology; ER: Endoplasmic reticulum

**Acknowledgements**

Not applicable.

**Authors’ contributions**

WL and YZ collected the clinical data and carried out the initial analyses, drafted the initial manuscript. QG and CW reviewed and revised the manuscript. The authors have read and approved the final manuscript.

**Authors’ information**

All authors belong to Department of Pediatrics, West China Second University Hospital, Sichuan University, No 20, 3rd section of Renmin South Road, Chengdu 610041, People’s Republic of China. Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, Chengdu, People’s Republic of China.

**Funding**

This project was supported by a grant from Pediatric Clinical Research Center Foundation of Sichuan Province, China (No.2017-46-4), National Science and Technology Major Project of China (No.2018ZX10103–001) the Fundamental Research Funds for Central Universities (No.201201717131) and Research development project of Sichuan Provincial Science and Technology Department (No.2018SZ0130). The views expressed are those of the authors and not necessarily those of funders. The funders were not directly involved in the collection, analysis, and interpretation of data or in writing the
manuscript. Prior to the grant being awarded, the funding body provided feedback on the study design.

Availability of data and materials
Not applicable.

Ethics approval and consent to participate
This study protocol was approved by the Ethical Committee of West China Second University Hospital, Sichuan University. Written informed consent was obtained from guardians of this patient prior to study enrollment.

Consent for publication
Written informed consent was obtained from the patient’s parents for the publication of this case report and all information contained in it.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Paediatrics, West China Second University Hospital, Sichuan University, Ministry of Education, Chengdu, PR China.
2Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, Chengdu, PR China.

Received: 4 December 2019 Accepted: 11 September 2020
Published online: 21 September 2020

References
1. Narkewicz MR, Dell Olio D, Karpen SJ, Murray KF, Schwarz K, Yazigi N, et al. Pattern of diagnostic evaluation for the causes of pediatric acute liver failure: an opportunity for quality improvement. J Pediatr. 2009;155(6):801-6 e801.
2. Dhawan A. Etiology and prognosis of acute liver failure in children. Liver Transpl. 2008;14(10):880-4.
3. Vilainho S, Choi M, Jain D, Malhotra A, Kulkarni S, Pashankar D, et al. Individual exome analysis in diagnosis and management of paediatric liver failure of indeterminate aetiology. J Hepatol. 2014;61(5):1056-63.
4. Maksimova N, Hara K, Nikolaeva I, Chun-Feng T, Usui T, Takagi M, et al. Neuroblastoma amplified sequence gene mutation: a rare cause of acute liver failure syndrome-2. Chin J Pediatr. 2019;57(6):487-8.
5. Ono S, Matsuda J, Watanabe E, Akaike H, Teranishi H, Miyata I, et al. Novel neuroblastoma amplified sequence (NBAS) mutations in a Japanese boy with fever-triggered recurrent acute liver failure. Hum Genome Var. 2019;6:2.
6. Staufner C, Haack TB, Kolker S, Thiel C, et al. Recurrent acute liver failure due to NBAS deficiency: phenotypic spectrum, disease mechanisms, and therapeutic concepts. J Inherit Metab Dis. 2016;39(1):3-16.
7. Li JQ, Qiu YL, Gong JY, Dou LM, Lu Y, Knieley AS, et al. Novel NBAS mutations and fever-related recurrent acute liver failure in Chinese children: a retrospective study. BMC Gastroenterol. 2017;17(1):27.
8. Staufner C, Haack TB, Kopke MG, Straub BK, Kolker S, Thiel C, et al. Recurrent acute liver failure due to NBAS deficiency: phenotypic spectrum, disease mechanisms, and therapeutic concepts. J Inherit Metab Dis. 2016;39(1):3-16.
9. Wang J, Pu ZJ, Lu ZH. Targeted next-generation sequencing reveals two novel mutations of NBAS in a patient with infantile liver failure syndrome-2. Mol Med Rep. 2018;17(2):2245–50.
10. Regateiro FS, Belkaya S, Neves N, Ferreira S, Silvestre P, Lemos S, et al. Recurrent elevated liver transaminases and acute liver failure in two siblings with novel bi-allelic mutations of NBAS. Eur J Med Genet. 2017;60(8):426–32.
11. Haack TB, Staufner C, Peters B, Wagner M, Alameer S, Baric I, Brosse P, et al. Defining clinical subgroups and genotype-phenotype correlations in NBAS-associated disease across 110 patients. Genet Med. 2020;22(3):610–21.
12. Cafi D, Giorgio E, Panteleoni F, Bruselles A, Barreì S, Riberi E, et al. NBAS pathogenic variants: defining the associated clinical and facial phenotype and genotype-phenotype correlations. Hum Mutat. 2019;40(6):721–8.
13. Wang J, Pu ZJ, Lu ZH. Targeted next-generation sequencing reveals two novel mutations of NBAS in a patient with infantile liver failure syndrome-2. Mol Med Rep. 2018;17(2):2245–50.
14. Wang J, Pu ZJ, Lu ZH. Targeted next-generation sequencing reveals two novel mutations of NBAS in a patient with infantile liver failure syndrome-2. Mol Med Rep. 2018;17(2):2245–50.
15. Wang J, Pu ZJ, Lu ZH. Targeted next-generation sequencing reveals two novel mutations of NBAS in a patient with infantile liver failure syndrome-2. Mol Med Rep. 2018;17(2):2245–50.
16. Regateiro FS, Belkaya S, Neves N, Ferreira S, Silvestre P, Lemos S, et al. Recurrent elevated liver transaminases and acute liver failure in two siblings with novel bi-allelic mutations of NBAS. Eur J Med Genet. 2017;60(8):426–32.
17. Haack TB, Staufner C, Peters B, Wagner M, Alameer S, Baric I, Brosse P, et al. Defining clinical subgroups and genotype-phenotype correlations in NBAS-associated disease across 110 patients. Genet Med. 2020;22(3):610–21.
18. Cafi D, Giorgio E, Panteleoni F, Bruselles A, Barreì S, Riberi E, et al. NBAS pathogenic variants: defining the associated clinical and facial phenotype and genotype-phenotype correlations. Hum Mutat. 2019;40(6):721–8.
19. Wang J, Pu ZJ, Lu ZH. Targeted next-generation sequencing reveals two novel mutations of NBAS in a patient with infantile liver failure syndrome-2. Mol Med Rep. 2018;17(2):2245–50.
20. Regateiro FS, Belkaya S, Neves N, Ferreira S, Silvestre P, Lemos S, et al. Recurrent elevated liver transaminases and acute liver failure in two siblings with novel bi-allelic mutations of NBAS. Eur J Med Genet. 2017;60(8):426–32.